Luina Benevides Lima

Luina Benevides Lima

Auto-generated profile, based on publicly available information

Luina Benevides Lima


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
LBLevi Azevedo Castelo Branco
Levi Azevedo Castelo Branco
Pedro SouzaPedro Souza
Pedro Souza
NNNilton Araripe dos Santos Neto
Nilton Araripe dos Santos Neto
TATawanny Kayonara Borges de Aguiar
Tawanny Kayonara Borges de Aguiar
ASAyrles F. B. Silva
Ayrles F. B. Silva
CFCleverson D. T. Freitas
Cleverson D. T. Freitas
Klebsiella pneumoniae is a multidrug-resistant opportunistic human pathogen related to various infections. As such, synthetic peptides have emerged as potential alternative molecules. Mo-CBP3-PepI has presented great activity against K. pneumoniae by presenting an MIC50 at a very low concentration (31.25 µg mL−1). Here, fluorescence microscopy and proteomic analysis revealed the alteration in cell membrane permeability, ROS overproduction, and protein profile of K. pneumoniae cells treated with Mo-CBP3-PepI. Mo-CBP3-PepI led to ROS overaccumulation and membrane pore formation in K. pneumoniae cells. Furthermore, the proteomic analysis highlighted changes in essential metabolic pathways. For example, after treatment of K. pneumoniae cells with Mo-CBP3-PepI, a reduction in the abundance of protein related to DNA and protein metabolism, cytoskeleton and cell wall organization, redox metabolism, regulation factors, ribosomal proteins, and resistance to antibiotics was seen. The reduction in proteins involved in vital processes for cell life, such as DNA repair, cell wall turnover, and protein turnover, results in the accumulation of ROS, driving the cell to death. Our findings indicated that Mo-CBP3-PepI might have mechanisms of action against K. pneumoniae cells, mitigating the development of resistance and thus being a potent molecule to be employed in producing new drugs against K. pneumoniae infections.

1 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FMFELIPE MESQUITA
FELIPE MESQUITA
Pedro SouzaPedro Souza
Pedro Souza
ESEmerson Lucena da Silva
Emerson Lucena da Silva
LLLuina Benevides Lima
Luina Benevides Lima
LOLaís Lacerda Brasil de Oliveira
Laís Lacerda Brasil de Oliveira
RMRaquel Montenegro
Raquel Montenegro
Despite advances in cancer chemotherapy, gastric cancer (GC) continues to have high recurrence rates and poor prognosis with limited treatment options. Understanding the etiology of GC and developing more effective, less harmful therapeutic approaches are vital and urgent. Therefore, this work describes a novel kinase target in malignant gastric cells as a potential therapeutic strategy. Our results demonstrate that among 147 kinase inhibitors (KI), only three molecules were significantly cytotoxic for the AGP-01 cell line. Hence, these three molecules were further characterized in their cellular mode of action. There was significant cell cycle impairment due to the expression modulation of genes such as TP53, CDKN1A, CDC25A, MYC, and CDK2 with subsequent induction of apoptosis. In fact, the Gene Ontology analysis revealed a significant enrichment of pathways related to cell cycle regulation (GO:1902749 and GO:1903047). Moreover, the three selected KIs significantly reduced cell migration and Vimentin mRNA expression after treatment. Surprisingly, the three KIs share the same target, ALK and INSR, but only the ALK gene was found to have a high expression level in the gastric cancer cell line. Additionally, lower survival rates were observed for patients with high ALK expression in TCGA-STAD analysis. In summary, we hypothesize that ALK gene overexpression can be a promising biomarker for prognosis and therapeutic management of gastric adenocarcinoma.

16 November 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
LBLevi Azevedo Castelo Branco
Levi Azevedo Castelo Branco
Pedro SouzaPedro Souza
Pedro Souza
NNNilton Araripe dos Santos Neto
Nilton Araripe dos Santos Neto
TATawanny Kayonara Borges de Aguiar
Tawanny Kayonara Borges de Aguiar
ASAyrles F. B. Silva
Ayrles F. B. Silva
CFCleverson D. T. Freitas
Cleverson D. T. Freitas
Klebsiella pneumoniae is a multidrug-resistant opportunistic human pathogen related to various infections. As such, synthetic peptides have emerged as potential alternative molecules. Mo-CBP3-PepI has presented great activity against K. pneumoniae by presenting an MIC50 at a very low concentration (31.25 µg mL-1). Here, fluorescence microscopy and proteomic analysis revealed the alteration in cell membrane permeability, ROS overproduction, and protein profile of K. pneumoniae cells treated with Mo-CBP3-PepI. Mo-CBP3-PepI led to ROS overaccumulation and membrane pore formation in K. pneumoniae cells. Furthermore, the proteomic analysis highlighted changes in essential metabolic pathways. For example, after treatment of K. pneumoniae cells with Mo-CBP3-PepI, it was seen a reduction in the abundance of protein related to DNA and protein metabolism, cytoskeleton and cell wall organization, redox metabolism, regulation factors, ribosomal proteins, and resistance to antibiotics. These reductions lead to the inhibition of DNA repair, inhibition of cell wall turnover, protein turnover, and ROS accumulation leading to cell death. Our findings indicated that Mo-CBP3-PepI might have mechanisms of action against K. pneumoniae cells, mitigating the development of resistance and thus being a potent molecule to be employed in producing new drugs against K. pneumoniae infections.

22 September 2023
Verified
Conference Paper
Open access
PDF file
GMGiselle Rabelo Matias
Giselle Rabelo Matias
LLLuina Benevides Lima
Luina Benevides Lima
COCarlos Eduardo DE Melo Oliveira
Carlos Eduardo DE Melo Oliveira
CPCarlos Roberto Koscky Paier
Carlos Roberto Koscky Paier
RMRaquel Montenegro
Raquel Montenegro
AQAna Rosa Pinto Quidute
Ana Rosa Pinto Quidute
INTRODUÇÃO: A Neoplasia Endócrina Múltipla tipo 1 (NEM-1) é uma síndrome hereditária autossômica dominante causada por mutações germinativas que predispõem ao desenvolvimento de tumores endócrinos e não endócrinos Após o diagnóstico de um indivíduo, a realização de rastreio genético e a orientação dos familiares sobre a síndrome é fundamental para a realização do diagnóstico precoce e para a prevenção dos agravos relacionados à síndrome. OBJETIVO: Avaliar os sintomas e descrever tumores de maior prevalência em indivíduos com mutação genética confirmada no gene MEN1 para NEM-1, após realização de rastreio familiar. MÉTODOS: Estudo transversal realizado, após aprovação em Comitê de Ética, a partir da aplicação de questionário acerca da existência de sinais e sintomas relacionados à síndrome familiar e da realização de teste genético. Foram incluídos pacientes com história familiar de parentes diagnosticados com a síndrome ou que apresentavam clínica sugestiva para NEM-1. RESULTADOS: Entre os 134 participantes do estudo, foram detectadas mutações em 31,34% dos participantes, entre os quais 54,77% eram do sexo masculino, com média de idade de 38 anos (variando entre 18-66 anos), 30,95% retiraram pelo menos um tumor e 97,6% possuíam pelo menos um sintoma. CONCLUSÃO: Cerca de um terço dos indivíduos testaram positivo para mutação no gene, de modo que os sintomas mais prevalentes foram os gastrointestinais e as lesões cutâneas. A realização do rastreio familiar permitiu aos pacientes o diagnóstico precoce, a partir dos testes genéticos, mesmo em pacientes oligossintomáticos.Sendo um estudo pioneiro na nossa região.

25 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
FMFelipe Pantoja Mesquita
Felipe Pantoja Mesquita
JSJean Breno Silveira da Silva
Jean Breno Silveira da Silva
LOLaís Lacerda Brasil de Oliveira
Laís Lacerda Brasil de Oliveira
LLLuina Benevides Lima
Luina Benevides Lima
Pedro SouzaPedro Souza
Pedro Souza
RMRaquel Montenegro
Raquel Montenegro
Angiotensin-converting enzyme 2 (ACE2) and the transmembrane serine protease 2 (TMPRSS2) are recognized as entry proteins of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and recently their Single Nucleotide Polymorphisms (SNP) have been studied in different populations to elucidate the impact on disease. The aim of this study was to evaluate the genetic SNP of ACE2 (rs35803318) and TMPRSS2 (rs2070788) genes in COVID-19 patients from Northeast Brazil compared with global populations, as well as the expression quantitative trait locus (eQTL). For ACE2 (rs35803318), we found 92.6% CC, 3.4% CT, and 4.0% TT genotype carriers in SARS-CoV-2-positive patients. Surprisingly, only the genotype frequencies of ACE2 SNP were not in Hardy-Weinberg equilibrium. For TMPRSS2 rs2070788, we found 22.3% GG, 50.7% AG, and 27% AA genotype carriers in SARS-CoV-2-positive patients. The expression quantitative trait loci (eQTLs) revealed that rs35803318 was associated with an altered PIR gene expression, and rs2070788 was found eQTLs association only with lung tissue. No significant association was identified between the genotype distribution of SNPs and the 'patient's outcome. In conclusion, our results suggest that ACE2 and TMPRSS2 may not be protective factors for global populations, including the Brazilian population, since the presence of SNPs does not affect the 'patient's outcome as described by other studies.